- Home
- SRZN vs ZURA Comparison
SRZN vs ZURA Comparison
Compare SRZN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- ZURA
- Stock Information
- Founded
- SRZN 2015
- ZURA 2022
- Country
- SRZN United States
- ZURA United States
- Employees
- SRZN N/A
- ZURA N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRZN Health Care
- ZURA Health Care
- Exchange
- SRZN Nasdaq
- ZURA Nasdaq
- Market Cap
- SRZN 82.8M
- ZURA 76.6M
- IPO Year
- SRZN N/A
- ZURA N/A
- Fundamental
- Price
- SRZN $7.10
- ZURA $1.11
- Analyst Decision
- SRZN Strong Buy
- ZURA Buy
- Analyst Count
- SRZN 2
- ZURA 7
- Target Price
- SRZN $38.50
- ZURA $14.33
- AVG Volume (30 Days)
- SRZN 11.0K
- ZURA 329.1K
- Earning Date
- SRZN 05-09-2025
- ZURA 05-08-2025
- Dividend Yield
- SRZN N/A
- ZURA N/A
- EPS Growth
- SRZN N/A
- ZURA N/A
- EPS
- SRZN N/A
- ZURA N/A
- Revenue
- SRZN $11,638,000.00
- ZURA N/A
- Revenue This Year
- SRZN N/A
- ZURA N/A
- Revenue Next Year
- SRZN N/A
- ZURA N/A
- P/E Ratio
- SRZN N/A
- ZURA N/A
- Revenue Growth
- SRZN N/A
- ZURA N/A
- 52 Week Low
- SRZN $6.00
- ZURA $0.97
- 52 Week High
- SRZN $18.17
- ZURA $6.35
- Technical
- Relative Strength Index (RSI)
- SRZN 31.40
- ZURA 39.10
- Support Level
- SRZN $9.96
- ZURA $1.17
- Resistance Level
- SRZN $11.56
- ZURA $1.30
- Average True Range (ATR)
- SRZN 0.96
- ZURA 0.12
- MACD
- SRZN -0.29
- ZURA -0.03
- Stochastic Oscillator
- SRZN 21.20
- ZURA 3.38
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.